Pipeline AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore project PharmaTimesQuantumCell gains global rights to NeuroRestore platform in deal worth over USD 2.2 billionNeuroscienceRead full story pharminent July 1, 2026 (Last updated: July 2, 2026) PharmaTimes QuantumCell gains global rights to NeuroRestore platform in deal worth over USD 2.2 billion Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot programNext: Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal Related Stories Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026 Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication pharminent August 10, 2026 Pipeline Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts pharminent August 5, 2026
